Outpatient setting: New study on DILAPAN-S for elective induction of labour in nulliparas

Date 02.08.2024

We are excited to announce the publication of a new study in Lancet eClinicalMedicine, showcasing the effectiveness and safety of DILAPAN-S for labor induction in nulliparous women, using an outpatient approach.

The study titled “Outpatient elective induction of labour at 39 weeks’ gestation (HOME INDUCTION): an open-label, randomized, controlled, phase III, non-inferiority trial” showcases the safety and efficacy of DILAPAN-S as a convenient outpatient option for cervical ripening.

Key findings

Key findings include:

High vaginal delivery rate: DILAPAN-S demonstrated a 75% success rate in vaginal deliveries with a 24-hour insertion period.
Safety assurance: No significant adverse maternal or neonatal outcomes were reported, confirming the safety profile of DILAPAN-S.
Reduced painful contractions: Significantly fewer participants using DILAPAN-S experienced painful contractions at home compared to those using dinoprostone.
Fewer unplanned early hospital returns: There were significantly fewer instances of unplanned early returns to the hospital among patients using DILAPAN-S, indicating effective management of the home-based cervical ripening process.
Women´s comfort: The option for outpatient ripening allows mothers to stay home during a significant part of the labour induction process, enhancing comfort and reducing stress.

Jan Waclav, MD, MEDICEM’s Medical & Clinical Affairs Director, commented on the results: ‘In addition to the positive outcomes mentioned, two intriguing findings emerged from the study that we do not yet fully understand. ‘First, a higher percentage of women in the DILAPAN-S groups received additional prostaglandin gel, despite similar median initial Bishop scores and subsequent Bishop score gains across all three groups (DILAPAN-S 12 hours, DILAPAN-S 24 hours and Propess 24 hours). Second, the D12 group had a lower percentage of vaginal births, even though the Bishop score gain after the first round of ripening was comparable to that in the D24 and P24 groups. We anticipate that further sub-analyses may provide clarity on these findings.‘

Read the full open-access article

We invite healthcare professionals to read the full open-access article to learn more about these promising results and the potential of DILAPAN-S in enhancing the labor induction experience.

Explore the open-access full study publication here. Stay connected with us at www.dilapan.com for the latest updates and insights into advanced labour induction solutions.